146 related articles for article (PubMed ID: 17062689)
1. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
Lagas JS; Vlaming ML; van Tellingen O; Wagenaar E; Jansen RS; Rosing H; Beijnen JH; Schinkel AH
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6125-32. PubMed ID: 17062689
[TBL] [Abstract][Full Text] [Related]
2. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.
Press RR; Buckle T; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2006 Jun; 57(6):819-25. PubMed ID: 16163538
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine.
Lagas JS; Damen CW; van Waterschoot RA; Iusuf D; Beijnen JH; Schinkel AH
Mol Pharmacol; 2012 Oct; 82(4):636-44. PubMed ID: 22767610
[TBL] [Abstract][Full Text] [Related]
4. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Bardelmeijer HA; Beijnen JH; Brouwer KR; Rosing H; Nooijen WJ; Schellens JH; van Tellingen O
Clin Cancer Res; 2000 Nov; 6(11):4416-21. PubMed ID: 11106262
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.
Tahara H; Kusuhara H; Fuse E; Sugiyama Y
Drug Metab Dispos; 2005 Jul; 33(7):963-8. PubMed ID: 15821041
[TBL] [Abstract][Full Text] [Related]
6. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.
Kemper EM; Cleypool C; Boogerd W; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2004 Feb; 53(2):173-8. PubMed ID: 14605863
[TBL] [Abstract][Full Text] [Related]
7. Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.
Chu C; Abbara C; Noël-Hudson MS; Thomas-Bourgneuf L; Gonin P; Farinotti R; Bonhomme-Faivre L
Biochem Pharmacol; 2009 May; 77(10):1629-34. PubMed ID: 19426700
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein (Abcb1) is involved in absorptive drug transport in skin.
Ito K; Nguyen HT; Kato Y; Wakayama T; Kubo Y; Iseki S; Tsuji A
J Control Release; 2008 Nov; 131(3):198-204. PubMed ID: 18725258
[TBL] [Abstract][Full Text] [Related]
9. Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein.
Bonhomme-Faivre L; Benyamina A; Reynaud M; Farinotti R; Abbara C
Addict Biol; 2008 Sep; 13(3-4):295-300. PubMed ID: 18331373
[TBL] [Abstract][Full Text] [Related]
10. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice.
Manford F; Riffo-Vasquez Y; Spina D; Page CP; Hutt AJ; Moore V; Johansson F; Forbes B
J Pharm Pharmacol; 2008 Oct; 60(10):1305-10. PubMed ID: 18812023
[TBL] [Abstract][Full Text] [Related]
11. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2.
Jamois C; Comets E; Mentré F; Marion S; Farinotti R; Bonhomme-Faivre L
Cancer Chemother Pharmacol; 2005 Jan; 55(1):61-71. PubMed ID: 15378273
[TBL] [Abstract][Full Text] [Related]
13. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
Gnoth MJ; Sandmann S; Engel K; Radtke M
Drug Metab Dispos; 2010 Aug; 38(8):1341-6. PubMed ID: 20413726
[TBL] [Abstract][Full Text] [Related]
14. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.
Smit JW; Huisman MT; van Tellingen O; Wiltshire HR; Schinkel AH
J Clin Invest; 1999 Nov; 104(10):1441-7. PubMed ID: 10562306
[TBL] [Abstract][Full Text] [Related]
15. Modulation of paclitaxel transport by flavonoid derivatives in human breast cancer cells. Is there a correlation between binding affinity to NBD of P-gp and modulation of transport?
Václavíková R; Boumendjel A; Ehrlichová M; Kovár J; Gut I
Bioorg Med Chem; 2006 Jul; 14(13):4519-25. PubMed ID: 16516478
[TBL] [Abstract][Full Text] [Related]
16. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
Gustafson DL; Long ME; Bradshaw EL; Merz AL; Kerzic PJ
Cancer Chemother Pharmacol; 2005 Sep; 56(3):248-54. PubMed ID: 15856231
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.
Kalvass JC; Olson ER; Pollack GM
Drug Metab Dispos; 2007 Mar; 35(3):455-9. PubMed ID: 17178769
[TBL] [Abstract][Full Text] [Related]
18. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted.
Smit JW; Schinkel AH; Weert B; Meijer DK
Br J Pharmacol; 1998 May; 124(2):416-24. PubMed ID: 9641561
[TBL] [Abstract][Full Text] [Related]
19. Transport of dietary phenethyl isothiocyanate is mediated by multidrug resistance protein 2 but not P-glycoprotein.
Ji Y; Morris ME
Biochem Pharmacol; 2005 Aug; 70(4):640-7. PubMed ID: 16002050
[TBL] [Abstract][Full Text] [Related]
20. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.
Huisman MT; Chhatta AA; van Tellingen O; Beijnen JH; Schinkel AH
Int J Cancer; 2005 Sep; 116(5):824-9. PubMed ID: 15849751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]